RxDoctor Payments Data

Thinh Ho, MD

Family Medicine · Tomball, TXNPI 1316180987

Payments from drug & device makers

$1,235in general payments, 2019–2025

Across 51 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$201
  • AstraZeneca$167
  • Novo Nordisk$159
  • Ivoclar Vivadent, Inc.$151
  • Boston Scientific$80
  • Otsuka America Pharmaceutical, Inc.$77
  • plus $400 from 13 others

What the payments were for

  • Food & beverage$1,08588%
  • Gifts$15112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,235 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$38,639
Medicare patients
70
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide27$36,675
EliquisApixaban40$34,463
JardianceEmpagliflozin11$19,806
OzempicSemaglutide14$15,292
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$9,050
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,666
Rosuvastatin Calcium112$2,829
Atorvastatin Calcium213$2,247
Olmesartan Medoxomil46$2,236
Duloxetine Hcl40$1,390
Ezetimibe20$1,238
Albuterol Sulfate HfaAlbuterol Sulfate48$1,155
Losartan Potassium95$1,064
Fluticasone Propionate43$922
Azelastine Hcl18$737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$23$36,67527 claims
PfizerEliquis$25$34,46340 claims
Novo NordiskOzempic$159$15,29214 claims
GSKTrelegy Ellipta$37$8,66613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Tomball

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →